{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:09:14Z","timestamp":1783764554843,"version":"3.55.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3836,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1002\/hep.20568","type":"journal-article","created":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T15:47:39Z","timestamp":1109087259000},"page":"595-602","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis"],"prefix":"10.1097","volume":"41","author":[{"given":"Karin","family":"Dilger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte H. J.","family":"Heeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20250325","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-25-20250325","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid: mechanisms of action and clinical use in hepatobiliary disorders","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J Hepatol"},{"key":"R3-25-20250325","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","article-title":"Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases","volume":"13","author":"Trauner","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-25-20250325","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double\u2010blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"key":"R5-25-20250325","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R6-25-20250325","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double\u2010blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R7-25-20250325","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"R8-25-20250325","first-page":"759","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R9-25-20250325","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long\u2010term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double\u2010blind controlled multicentric trial","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"R10-25-20250325","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R11-25-20250325","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"R12-25-20250325","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten\u2010year survival in ursodeoxycholic acid\u2010treated patients with primary biliary cirrhosis","volume":"29","author":"Poupon","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R13-25-20250325","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic\u2010acid therapy for primary biliary cirrhosis: a meta\u2010analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"R14-25-20250325","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"key":"R15-25-20250325","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"1","author":"Gluud","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-25-20250325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P\u2010450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R17-25-20250325","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3A","volume":"38","author":"Thummel","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R18-25-20250325","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P\u2010450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-25-20250325","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/phgs.5.3.243.29833","article-title":"Genetic variability in CYP3A5 and its possible consequences","volume":"5","author":"Xie","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R20-25-20250325","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","article-title":"The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?","volume":"41","author":"Doherty","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R21-25-20250325","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.510300332","article-title":"Bile acid structure and selective modulation of murine hepatic cytochrome P450\u2010linked enzymes","volume":"30","author":"Paolini","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R22-25-20250325","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/jhep.2002.34939","article-title":"Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up\u2010regulation of CYP [correction of CXP] and preservation of BSEP activities","volume":"36","author":"Paolini","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R23-25-20250325","doi-asserted-by":"crossref","first-page":"39411","DOI":"10.1074\/jbc.M106340200","article-title":"Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450","volume":"276","author":"Schuetz","year":"2001","journal-title":"J Biol Chem"},{"key":"R24-25-20250325","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4beta\u2010hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"R25-25-20250325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0090-9556(25)06497-9","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"Jonsson","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"R26-25-20250325","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double\u2010blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"R27-25-20250325","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early\u2010 and late\u2010stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R28-25-20250325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00228-003-0690-3","article-title":"Urinary 6\u03b2\u2010hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and animals","volume":"59","author":"Galteau","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-25-20250325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0378-4347(94)00265-7","article-title":"Simultaneous determination of urinary free cortisol and 6beta\u2010hydroxycortisol by high\u2010performance liquid chromatography to measure human CYP3A activity","volume":"660","author":"Lykkesfeldt","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R31-25-20250325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo\u2010controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R32-25-20250325","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0168-8278(00)80385-2","article-title":"Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use","volume":"32","author":"Prince","year":"2000","journal-title":"J Hepatol"},{"key":"R33-25-20250325","first-page":"120","article-title":"Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease","volume":"21","author":"George","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R34-25-20250325","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.1840380424","article-title":"Sex is a major determinant of CYP3A4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R35-25-20250325","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampicin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R36-25-20250325","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long\u2010term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"key":"R37-25-20250325","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1365-2036.2003.01458.x","article-title":"Review article: pruritus in cholestatic and other liver diseases","volume":"17","author":"Mela","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-25-20250325","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1440-1746.2002.02717.x","article-title":"Extrahepatic manifestations of cholestasis","volume":"17","author":"Glasova","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R39-25-20250325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.42.111901.111051","article-title":"Regulation of CYP3A gene transcription by the pregnane X receptor","volume":"42","author":"Goodwin","year":"2002","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R40-25-20250325","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","article-title":"Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin","volume":"276","author":"Geick","year":"2001","journal-title":"J Biol Chem"},{"key":"R41-25-20250325","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.36591","article-title":"The human bile salt export pump: characterization of substrate specificity and identification of inhibitors","volume":"123","author":"Byrne","year":"2002","journal-title":"Gastroenterology"},{"key":"R42-25-20250325","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin. Clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R43-25-20250325","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin","volume":"24","author":"Fromm","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R44-25-20250325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P\u2010glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"Von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R45-25-20250325","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00054725-200409000-00012","article-title":"Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P\u2010glycoprotein","volume":"10","author":"Dilger","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R46-25-20250325","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0168-8278(03)00410-0","article-title":"Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis","volume":"39","author":"Kojima","year":"2003","journal-title":"J Hepatol"},{"key":"R47-25-20250325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00315399","article-title":"Time course of the changes in prednisolone pharmacokinetics after co\u2010administration or discontinuation of rifampicin","volume":"45","author":"Lee","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"R48-25-20250325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration\u2010time curve for oral midazolam is 400\u2010fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R49-25-20250325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P\u2010glycoprotein in the interaction of digoxin and rifampicin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20568","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200503000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:25:52Z","timestamp":1743096352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200503000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20568","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}